Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.

Semin Cutan Med Surg

Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.

Published: September 2018

Hidradenitis suppurativa (HS) is a frequently devastating inflammatory skin disorder. Although many treatments have been tried and tested to date, there is only one Food and Drug Administration-approved treatment option, adalimumab, which is currently indicated for moderateto- severe HS. Our understanding of the management of HS with biologic agents and with nonantibiotic and/ or antimicrobial systemic therapies continues to evolve. In this article, we summarize the existing data on biologics and other small-molecule systemic agents, as well as share our personal experiences with the pharmacological management of HS in the clinical setting. Continued challenges that limit our ability to study and treat this disease effectively include a lack of a universally employed scoring system for disease severity, high variability in clinical presentation, high cost of off-label therapy, and the scarcity of long-term studies on treatment response and medication safety.

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.042DOI Listing

Publication Analysis

Top Keywords

hidradenitis suppurativa
8
overview update
4
update biologic
4
biologic therapy
4
therapy moderate-to-severe
4
moderate-to-severe hidradenitis
4
suppurativa hidradenitis
4
suppurativa frequently
4
frequently devastating
4
devastating inflammatory
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!